SCHEMBL7138024

SCHEMBL7138024

Cc1ccc(CNCc2cccc(-c3cnc(-c4ccc(F)cc4)[nH]3)c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SSTR3 P32745 4/20 0.47
BACE1 P56817 1/20 0.44
NPY5R Q15761 3/20 0.44
HPGDS O60760 2/20 0.44
SCN2A Q99250 4/20 0.42
SMN1; SMN2 Q16637 1/20 0.40
SMPD3 Q9NY59 1/20 0.40
AURKA O14965 1/20 0.40
ABL1 P00519 1/20 0.40
NTRK1 P04629 1/20 0.40
LCK P06239 1/20 0.40
CSF1R P07333 1/20 0.40
RET P07949 1/20 0.40
MET P08581 1/20 0.40
PDGFRB P09619 1/20 0.40
PIM1 P11309 1/20 0.40
PDGFRA P16234 1/20 0.40
FLT3 P36888 1/20 0.40
MAPK8 P45983 1/20 0.40
CDK8 P49336 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7141176 0.92 CYP1A2 (0.46) SSTR3BACE1NPY5RHPGDSSCN2A
SCHEMBL7179734 0.87 BACE1 (0.47) BACE1NPY5RHPGDSSCN2A
SCHEMBL7143626 0.85 BACE1 (0.45) BACE1NPY5RHPGDSSCN2A
SCHEMBL7187293 0.84 BACE1 (0.44) SSTR3BACE1NPY5RHPGDSSCN2A
SCHEMBL8118487 0.83 CYP1A2 (0.41) SSTR3HPGDSSCN2A
SCHEMBL7142281 0.83 SCN2A (0.47) BACE1NPY5RHPGDSSCN2A
SCHEMBL8110914 0.83 CYP1A2 (0.44) BACE1NPY5RHPGDSSCN2ASMN1; SMN2
SCHEMBL7140173 0.83 BACE1 (0.43) BACE1NPY5RHPGDSSCN2A
SCHEMBL7138181 0.82 HPGDS (0.49) BACE1NPY5RHPGDSSCN2A
SCHEMBL7143623 0.82 BACE1 (0.46) SSTR3BACE1NPY5RHPGDSSCN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US claimed
US-6515133-B1 Certain diaryl imidazoles act as partial agonists or antagonists for NPY receptors, in particular NPY 5 receptors. They are of use, for example in treating loss of appetite. Such compounds bear aryl groups in the 2 position. NEUROGEN CORPORATION 2003-02-04 US disclosed
US-6121260-A Method of treating conditions susceptible to modulation of NPY receptors with diarylimidazole derivatives NEUROGEN CORPORATION (US) 2000-09-19 US disclosed